Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Oncologist. 2019 Feb;24(2):e80-e82. doi: 10.1634/theoncologist.2018-0285. Epub 2018 Nov 2.
Human epidermal growth factor receptor 2 (HER2)-targeted antibodies, including pertuzumab and trastuzumab, improve overall survival and progression-free survival among women with HER2-positive metastatic breast cancer, but grade ≥3 cardiotoxicity occurs in approximately 8% of cases. Here we report a case of Takotsubo cardiomyopathy associated with the use of dual anti-HER2 therapy in a 63-year-old woman who presented to the emergency department with an 8- to 10-hour history of progressive dyspnea after completing her third cycle of pertuzumab plus trastuzumab in addition to nab-paclitaxel chemotherapy. To our knowledge, this patient represents the first reported case of Takotsubo cardiomyopathy associated with pertuzumab plus trastuzumab combination therapy in the literature.
人表皮生长因子受体 2（HER2）靶向抗体，包括帕妥珠单抗和曲妥珠单抗，可改善 HER2 阳性转移性乳腺癌女性的总生存期和无进展生存期，但约 8%的病例会发生≥3 级的心脏毒性。在这里，我们报告了一例与双 HER2 治疗相关的 Takotsubo 心肌病，该患者为 63 岁女性，在接受帕妥珠单抗联合曲妥珠单抗加 nab-紫杉醇化疗的第三个周期后 8-10 小时出现进行性呼吸困难，就诊于急诊科。据我们所知，该患者是文献中首例报告的与帕妥珠单抗联合曲妥珠单抗联合治疗相关的 Takotsubo 心肌病病例。
